Completed
Pharmacokinetics and Bioavailability of Liquid vs Tablet Buprenorphine
Led by National Institute on Drug Abuse (NIDA) · Updated on 2017-01-12
1
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the steady-state pharmacokinetics and bioavailability of buprenorphine sublingual tablets vs. sublingual solution.
CONDITIONS
Official Title
Evaluation of Liquid vs. Tablet Buprenorphine - 6
Who Can Participate
Eligibility Criteria
You may qualify if you...
M/F ages 21-50. Meet DSM-IV criteria for opioid dependence. Agree to conditions of the study and sign informed consent.
You will not qualify if you...
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
Trial Site Locations
Total: 1 location
1
Friends Research Institute
Los Angeles, California, United States, 90025
Status Unknown
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here